目的 系統(tǒng)評價卡貝縮宮素對比縮宮素預防產(chǎn)后出血的臨床療效和安全性。方法 計算機檢索EMbase、PubMed、中國期刊全文數(shù)據(jù)庫（CNKI）、維普中文科技期刊全文數(shù)據(jù)庫（VIP）、中國生物醫(yī)學文獻數(shù)據(jù)庫（CBM）和萬方數(shù)據(jù)庫，收集卡貝縮宮素對比縮宮素用于預防產(chǎn)后出血的隨機對照研究（RCT），檢索時限均從2000年1月至2017年12月。由2位研究者篩選文獻、提取資料，采用Rev Man 5.1軟件進行Meta-分析。結果 共納入14個RCTs，3 052例患者。Meta-分析結果顯示相對于縮宮素，卡貝縮宮素能顯著降低產(chǎn)后出血率[OR=0.48，95% CI（0.36~0.63），P<0.001]，術中出血量[MD=-67.31，95% CI（-86.34~-48.28），P<0.001]、術后2 h出血量[MD=-50.43，95% CI（-71.32~-29.55），P<0.001]和術后24 h出血量[MD=-62.87，95% CI（-85.59~-40.16），P<0.001]；血紅蛋白減少[MD=-4.24，95% CI（-6.16~-2.31），P<0.001]和不良反應發(fā)生率[OR=0.52，95% CI（0.41~0.65），P<0.001]。結論 本研究結果顯示卡貝縮宮素預防產(chǎn)后出血的臨床療效和安全性優(yōu)于縮宮素，值得臨床推廣。

Objective To evaluate the effectiveness and safety of caebetocin vs oxytocin in prevention of postpartum hemorrhage of cesarean section. Methods The related literatures were searched in the following databases:PubMed, EMbase, CNKI, VIP, and WanFang Data from January 2000 to December 2017. Randomized controlled trial (RCT) of caebetocin vs oxytocin in prevention of postpartum hemorrhage of cesarean section was included. Two reviewers independently screened literatures and extracted data. Meta-analysis was conducted by RevMan 5.1 software. Results A total of 14 RCTs were collected, including 3 052 patients. The Meta-analysis showed that:compared with oxytocin, caebetocin could significantly reduce the rate of postpartum hemorrhage[OR=0.48, 95% CI(0.36~0.63), P<0.001]; intraoperative bleeding[MD=-67.31, 95% CI(-86.34~-48.28), P<0.001], postoperative 2 h bleeding[MD=-50.43, 95% CI(-71.32~-29.55), P<0.001], and postoperative 24 h bleeding[MD=-62.87, 95% CI(-85.59~-40.16), P<0.001]; hemoglobin reduction[MD=-4.24, 95% CI(-6.16~-2.31), P<0.001] and incidence of adverse reactions[OR=0.52,95% CI(0.41~0.65), P<0.001]. Conclusion The results of this study showed that the clinical efficacy and safety of caebetocin is better than oxytocin in prevention of postpartum hemorrhage, and it is worthy of clinical use.